Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02715141
Previous Study | Return to List | Next Study

Molecular Stool Testing for Colorectal Cancer Surveillance (MOCCAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02715141
Recruitment Status : Unknown
Verified June 2016 by The Netherlands Cancer Institute.
Recruitment status was:  Recruiting
First Posted : March 22, 2016
Last Update Posted : June 20, 2016
Sponsor:
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Maastricht University Medical Center
Information provided by (Responsible Party):
The Netherlands Cancer Institute

Brief Summary:

Rationale: Since January 2014 the Dutch screening programme for bowel cancer has been implemented. Screening will increase the demand for surveillance. Although patients in whom adenomas have been removed are at increased risk of progressing to cancer, solid evidence on the reduction of death from CRC through the current colonoscopy-based surveillance is lacking. Furthermore, colonoscopy-based surveillance leads to high logistic demands, high individual burden and high costs. Therefore, there is need for new surveillance strategies. Stool-based molecular testing (Cologuard®, consisting of a stool DNA test and an immunochemical assay for human hemoglobin) or Faecal Immunochemical Testing (FIT) may serve as an alternative for colonoscopy surveillance.

The aim of this study is to compare the accuracy of an established molecular stool test (Cologuard®) and FIT to colonoscopy for detection of advanced adenomas or CRC (advanced neoplasia) in a surveillance population. These outcomes will be used to model various strategies of stool-based molecular surveillance to inform health policy decisions.


Condition or disease Intervention/treatment
Colorectal Cancer Behavioral: Collection of stool sample

Detailed Description:

BACKGROUND: Since January 2014 the Dutch screening programme for colorectal carcinoma (CRC) has been implemented. Screening will increase the demand for surveillance. However, solid evidence on the reduction of death from CRC through the current colonoscopy-based surveillance is lacking. Furthermore, colonoscopy-based surveillance leads to high logistic demands, high patient burden and high costs. Therefore, there is need for new surveillance strategies. Stool-based molecular testing (Cologuard®) or Faecal Immunochemical Testing (FIT) may serve as an alternative for colonoscopy surveillance.

OBJECTIVES:

  1. To compare the accuracy of an established molecular stool test (Cologuard®) and FIT to colonoscopy for detection of advanced adenomas or CRC (advanced neoplasia) in a surveillance population.
  2. To model various strategies of stool-based molecular surveillance to inform health policy decisions.

MATERIALS AND METHODS: In this prospective observational cross-sectional cohort study, individuals aged 50-75 years that are scheduled for surveillance colonoscopy will be invited to participate. They are asked to collect a whole-stool sample prior to the surveillance colonoscopy. The sample will be used to test for the presence of molecular stool markers. The results of the molecular stool test and FIT will be compared to the colonoscopy findings.

EXPECTED RESULTS: Frequent surveillance using stool-based molecular testing is more cost-effective than the current colonoscopy-based surveillance.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 4000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Molecular Stool Testing for Colorectal Cancer Surveillance
Study Start Date : October 2015
Estimated Primary Completion Date : July 2017
Estimated Study Completion Date : July 2017

Resource links provided by the National Library of Medicine



Intervention Details:
  • Behavioral: Collection of stool sample
    Collection of stool sample prior to the scheduled surveillance colonoscopy.


Primary Outcome Measures :
  1. accuracy of molecular stool test (Cologuard) and FIT [ Time Frame: Patient inclusion for the calculation of the accuracies is expected to take 2-3 years. ]
    The accuracy (sensitivity, specificity, PPV and NPV) of the molecular stool test (Cologuard®) and FIT compared to colonoscopy in the detection of advanced neoplasia in a surveillance population.

  2. cost-effectiveness of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model [ Time Frame: This will be calculated when all accuracy data (outcome 1) are available. This is expected to be 6 months after end of study. ]
    Cost-effectiveness of multiple surveillance strategies, using test performance data as input in the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model.

  3. life time health effects of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model [ Time Frame: This will be calculated when all accuracy data (outcome 1) are available. This is expected to be 6 months after end of study. ]
    The ASCCA model will be used to predict outcomes, including cancer incidence and mortality, for different surveillance strategies.


Secondary Outcome Measures :
  1. risk of CRC [ Time Frame: up to one month after surveillance colonoscopy ]
    Risk factors for detecting advanced colonic neoplasia have been identified, of which the most established include gender, age, BMI, family history, physical activity, nutritional habits and smoking. Participants will be asked to complete a validated online questionnaire evaluating these risk factors.

  2. presence of Cologuard marker pannel on resected tissue of polyps [ Time Frame: Analysis will be performed during the study and approximately 1 year after end of study ]
    A challenge associated with the use of molecular markers is to find a panel of markers that represents the heterogeneity of the tumour. Therefore it is of interest to analyse whether the markers included in the Cologuard are present in the tissue of resected polyps.

  3. presence of previously identified progression biomarker on resected tissue samples of polyps [ Time Frame: Analysis will be performed during the study and approximately 1 year after end of study ]
    The identification of biomarkers involved in the progression from colorectal adenoma to carcinoma (progression biomarkers) could aid better risk-stratification of adenomas and thereby decrease over-diagnosis and over-treatment . As a secondary objective we will therefore analyse previously identified progression biomarkers in the tissue samples of polyps obtained during colonoscopy.


Biospecimen Retention:   Samples With DNA
Stool samples will be collected. The stool samples will be used to test for the presence of molecular stool markers.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The intended population of this study consists all subjects in the participating centres that are elected for colonoscopy surveillance.
Criteria

Inclusion Criteria:

  • Subjects in the age group 50-75 years. The lower age limit is set at 50 years because of the high probability of familiar predisposition when advanced neoplasm is present in a younger age group.26 The upper age limit of 75 years is in correspondence with the recommended stop-age for surveillance according to the current guideline.9
  • Subjects with an indication for surveillance colonoscopy according to the previous guideline ('Follow up after polypectomy', 2002; summarized in 2008) or current ('Colonoscopy Surveillance', 2013) guideline. This includes subjects with a history of CRC or polypectomy, as well as subjects under surveillance for familial colorectal carcinoma (FCC).
  • Subjects who have sufficient comprehension of the Dutch language.
  • Subjects who have given their informed consent.

Exclusion criteria:

  • Subjects with inflammatory bowel disease (IBD)
  • Subjects with Lynch syndrome, familial adenomatous polyposis (FAP), attenuated FAP (AFAP), MUTYH associated polyposis (MAP) and serrated polyposis syndrome (SPS)
  • Subjects with a previous colonoscopy < 6 months (rescopy)
  • Subjects with proctocolectomy
  • Subjects with life expectancy < 3 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02715141


Locations
Layout table for location information
Netherlands
Nethelands Cancer Institute Recruiting
Amsterdam, Noord-Holland, Netherlands, 1066 CX
Contact: Meta CJ van Lanschot, MD    003120 5129111 ext 7913    m.v.lanschot@nki.nl   
Contact: Gerrit A Meijer, MD, PhD    003120 5129111 ext 7998    g.meijer@nki.nl   
Principal Investigator: Evelien Dekker, MD, PhD         
Principal Investigator: Manon van Engeland, PhD         
Sponsors and Collaborators
The Netherlands Cancer Institute
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Maastricht University Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: The Netherlands Cancer Institute
ClinicalTrials.gov Identifier: NCT02715141     History of Changes
Other Study ID Numbers: M15MOC
NL52708.018.15 ( Other Identifier: CCMO, the Netherlands )
First Posted: March 22, 2016    Key Record Dates
Last Update Posted: June 20, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by The Netherlands Cancer Institute:
surveillance, molecular stool testing
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases